Clinical Neuroscience

[Repeated stroke, psychotic episode - primary antiphospholipid syndrome?]

CSIBRI Éva1, FARKAS Márta1

NOVEMBER 20, 1996

Clinical Neuroscience - 1996;49(11-12)

[The antiphospholipid syndrome described some 10 years ago is characterized by a predisposition to arterial and venous thrombosis and the presence of antiphospholipid antibodies. It is often associated with systemic lupus erythematosus, but its primary forms are also well known. Its clinical features are well known in neurology as well as in psychiatry. In this paper we present a case report with therapeutic implications. We discuss the importance of reccurent stroke at a young age in association with the possibility of a rare manifestation of antiphospholipid syndrome: organic brain disease, appearing in the form of schizoaffective psychopathological symptoms.]

AFFILIATIONS

  1. SOTE Pszichiátriai és Pszichoterápiás Klinika, Budapest

COMMENTS

0 comments

Further articles in this publication

Clinical Neuroscience

[Cluster headache and its treatment]

JELENCSIK Ilona

[Cluster headache, one of the most painful conditions known, is encountered infrequently in clinical practice. It is characterized by recurrent, unilateral attacks of severe intensity, brief duration and often accompanied by signs and symptoms of autonomic dysfunction. The actual cause of the pain has not been fully elucidated, but most authors believe that the pain arises as a result of a local vasodilatation with a release of certain neuropeptides to the perivascular tissues, resulting in sterile neurogenic inflammation and oedema. Aetiology is absolutely unknown. Treatment can be given as prophylaxis and/or as a symptomatic acute therapy for individual attacks. In the prophylaxis of episodic cluster headache ergotamine, calciumentry blockers, serotonin inhibitors and steroids are used. In chronic cluster headache lithium is the drug of choice, but verapamil may also be tried. Acute therapy has included ergotamine, oxygen inhalation and sumatriptan. Rarely, surgical intervention may be considered.]

Clinical Neuroscience

[Experiences with sumatriptan in the treatment of Cluster headache]

JELENCSIK Ilona, BOZSIK György, ÁFRA Judit, ERTSEY Csaba

[Subcutaneously administered sumatriptan 6 mg is rapid, effective and well-tolerated for the acute treatment of cluster headache. Efficacy is maintained in long-term use. The authors report the results of the 5HT1 receptor agonist sumatriptan autoinjector in the treatment of 350 attacks in 20 cluster patients. After 20 minutes post injection the complete dissolution of headache was reported in 95% of the attacks. Slight and transient side-effects were experienced therefore non of the patients were discouraged from using the autoinjector device again. It is essential in the improvement of the quality of life of patients suffering from cluster headache.]

Clinical Neuroscience

[Quantitative monitoring of EEG variability following subarachnoid hemorrhage]

JUHÁSZ Csaba, VESPA Paul, NUWER R. Marc, MARTIN Neil

[Cerebral vasospasm causing focal ischemia is a frequent complication following subarachnoid hemorrhage. Monitoring of EEG may help to reveal hemispheric dysfunction in the postoperative period. Continuous monitoring of EEG was performed on 8 bipolar channel in 30 patients with subarachnoid hemorrhage during the first two weeks after aneurysm rupture. Computerized trend analysis of 8–16 hours long periods was made. Variability of relative alpha power was evaluated visually on a 4 grade scale and it was also measured quantitatively. EEG data were compared with daily transcranial Doppler values and clinical state. Symptomatic vasospasm was detected in 16 patients while other neurological complications developed in a further 4 cases during monitoring. Significant decrease of variability was observed in all of them. This change developed 1-2 days before other signs of vasospasm in 10 patients. The onset of variability decrease was unilateral in 4 cases. No remarkable decrease of variability was found in patients without neurological complication. Our data confirm that EEG monitoring is a useful tool for sensitively detecting deterioration of brain function. Relative alpha variability is an indicative EEG parameter that can signify hemispheric dysfunction caused by ischemia in an early subclinical stage, when still no Doppler signs of vasospasm or deterioration of clinical symptoms occur.]

Clinical Neuroscience

[Intravenous perfusion anaesthesia in neurosurgey part two]

HUDVÁGNER Sándor, SZENOHRADSZKY Katalin, VIDA Gabriella, DÓCZI Tamás

[A retrospective analysis of 1300 neurosurgical perfusion narcoses performed by means of intravenously administered propofol-fentanyl-vecuron proved the advantage of this technique over traditional procedures. It decreased the recovery time, the incidence of postoperative nausea and vomiting, and muscle fibrillation. Propofol did not elevate either raised or normal intracranial pressures. Moreover, a trend reduction of raised ICP was observed. The incidence of cardiovascular complications was also reduced. Patients, especially the elderly, had a quick, subjectively well-tolerated induction of sleep and recovery. Comparison of parameters of propofol general anaesthesia with those of "combined balanced narcosis" and "perfusion ataranalgesia” statistically proved the significantly advantage of this new method. The conclusion has been drawn that propofol was a most appropriate drug for neurosurgical anaesthesia. ]

Clinical Neuroscience

[Post-traumatic ischemic stroke in childhood]

VELKEY Imre, LOMBAY Béla

[A report is given about two children with post-traumatic ischemic stroke. In the first case a blunt head injury, in the second case a minor cervical trauma caused the ischemic cerebrovascular episodes. The diagnosis was made after repeated CT scans by the help by sonography. The possible traumatic origin of acute hemiparesis due to ischemic stroke in children is emphasized. ]

All articles in the issue

Related contents

Hungarian Immunology

[Detection of rare phospholipid/co-factor antibodies in lupus patients]

TARR Tünde, KISS Emese, BÓTYIK Balázs, TUMPEK Judit, SOLTÉSZ Pál, ZEHER Margit, SZEGEDI Gyula, LAKOS Gabriella

[OBJECTIVE - Was to detect the rare phospholipid/ co-factor autoantibodies in lupus patients. PATIENTS AND METHODS - In the present study, besides anti-cardiolipin and anti-β2-glycoprotein I, antibodies directed against phosphatidil-serine, protrombin and annexinV were measured by commercial ELISA kits in 85 randomly selected lupus patients, 14 of whom met the criteria of antiphospholipid syndrome. Corralations were determined between the presence and concentration of rare antiphospholipids and those included in the diagnostic criteria of antiphospholid syndrome, as well as with clinical thrombotic manifestations. RESULTS - Anti-cardiolipin IgG was positive in 14 patients, aCL IgM in eight, anti-β2GPI IgG in four and IgM in five patients. Lupus anticoagulant was detected in nine cases. Seven patients were positive for anti-phosphatidilserine IgG, nine for aPS IgM, anti-protrombin IgG was positive in nine cases. Antiprotrombin IgM and anti-annexinV were negative in all patients. Correlation was found between antiphosphatidilserine and anti-cardiolipin antibodies. The frequency and the concentration of rare antiphospholipid/ co-factor antibodies were higher in patients with secondray antiphospholipid syndrome. The presence of such rare antiphospholipid antibodies cumulated in patients with antiphospholipid syndrome. Their presence increased the frequency of thrombotic events in the entire study population, furthermore in those positive for lupus anticoagulant or anti-cardiolipin. CONCLUSIONS - The rare anti-phospholipid/cofactor antibodies were found in 12% of an unselected cohort of lupus patients. Their presence was more frequent in patients with secondary antiphospholipid syndrome, and further increased the risk of thrombotic complications.]

Lege Artis Medicinae

[ANTICOAGULATION IN OBSTETRICS]

DOMJÁN Gyula, GADÓ Klára

[The risk of thrombosis is increased about 5 to10 times during pregnancy and in the puerperium. Beside the classic risk factors, this is also due to special obstetrical causes. Delivery, especially Cesarean section further increases susceptibility to thrombosis. Prophylactic or therapeutic anticoagulant treatment can significantly reduce maternal and fetal morbidity and mortality. Just like in the non-pregnant state, subcutaneous low molecular weight heparin or intravenous or subcutaneous unfractionated heparin is recommended in pregnancy if anticoagulation is indicated. Warfarin is contraindicated in the first trimester because of its teratogenicity and also in the third trimester because of its long-lasting effect. Heparin does not cross the placenta, but its long-term administration may cause several side effects. Dosage, starting time and duration of the treatment depend on the measure of the risk of thrombosis. In certain cases (such as antiphospholipid syndrome) anticoagulant therapy is supplemented by low-dose acetylsalicylic acid. The date of delivery can be electively planned to minimalize bleeding and thrombotic complications. Vaginal delivery is preferred because of its lower risk of bleeding compared to Cesarean section. Intensity of anticoagulant therapy in the peripartum period should depend on the risk of thrombosis. The third phase of delivery should be actively driven by giving oxytocin to avoid bleeding complications. Since anticoagulant therapy is often continued during breast-feeding, it is important to know that neither warfarin, nor heparin is secreted in milk. When planning the treatment, each case requires individual consideration based on the type and number of risk factors, gestation time and, importantly, compliance of the patient.]

Hungarian Immunology

[Antiphospholipid syndrome - focused on the childhood form]

KÁLOVICS Tamás, PONYI Andrea, BENSE Tamás, MÜLLER Judit, DANKÓ Katalin, FEKETE György, CONSTANTIN Tamás

[Antiphospholipid syndrome is an autoimmune disorder characterized by recurrent thromboembolic events with concurrent presence of antiphospholipid antibodies in the sera. The morbidity and mortality of the syndrome is defined by the clinical manifestations: deep vein thrombosis, cerebrovascular events, myocardial infarct, pulmonary embolism, recurrent pregnancy losses and prematurity. The authors reviewed the pathogenesis, the clinical course and the treatment of the antiphospholipid syndrome focused on the childhood form.]

Lege Artis Medicinae

[Antiphospholipid syndrome]

GERGELY Péter

[Antiphospholipid syndrome is a recently recognized clinical entity characterized by the presence of deep vein and cerebral thrombosis, thrombocytopenia and recurrent fetal loss. The syndrome is caused by autoantibodies directed against phospholipid antigens. The clinical syndrome is most frequently associated with systemic lupus erythematosus.]